Wells Fargo Starts AxoGen, Inc. (AXGN) at Overweight

Wells Fargo analyst Larry Biegelsen initiates coverage on AxoGen, Inc. (NASDAQ: AXGN) with a Overweight rating and a price target of $40.00.

The analyst comments: "AXGN is the only company fully focused on the treatment of peripheral nerve injuries. Its lead product, Avance, is an off‑the‑shelf biologic nerve graft that supports regeneration without harvesting a patient’s own nerve, unlike autograft, which is the gold standard in nerve repair. Avance has no direct biologic competitor in the market or in development, providing a clear first‑mover advantage. The opportunity for Avance reflects both (1) share gains from autograft and (2) market growth, as greater awareness of nerve injury is expanding repair rates. The US TAM spans Extremities ($2.9B), OMF/H&N ($1.2B), Breast Recon ($677M), and Prostate ($754M). We estimate overall AXGN's penetration is ~3.2% today, growing to 4.6% by 2028, which is driven by double-digit procedure volume across all segments."

For an analyst ratings summary and ratings history on AxoGen, Inc. click here. For more ratings news on AxoGen, Inc. click here.

Shares of AxoGen, Inc. closed at $35.25 yesterday.

You May Also Be Interested In